Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse
- 5 November 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 114 (19) , 4027-4033
Abstract
Laromustine is a sulfonylhdrazine alkylator with significant antileukemia activity. An international, randomized (2:1), double-blind, placebo-controlled study was conducted to compare complete remission (CR) rates and overall survival (OS) in patients with first relapse acute myeloid leukemia (AML) treated with laromustine and high-dose cytarabine (HDAC) versus HDAC/placebo. Patients received 1.5 g/m2 per day cytarabine continuous infusion for 3 days and laromustine 600 mg/m2 (n = 177) or placebo (n = 86) on day 2. Patients in CR received consolidation with laromustine/HDAC or HDAC/placebo as per initial randomization. After interim analysis at 50% enrollment, the Data Safety Monitoring Board (DSMB) expressed concern that any advantage in CR would be compromised by the observed on-study mortality, and enrollment was held. The CR rate was significantly higher for the laromustine/HDAC group (35% vs 19%, P = .005). However, the 30-day mortality rate and median progression-free survival were significantly worse in this group compared with HDAC/placebo (11% vs 2%; P = .016; 54 days vs 34; P = .002). OS and median response durations were similar in both groups. Laromustine/HDAC induced significantly more CR than HDAC/placebo, but OS was not improved due to mortality associated with myelosuppression and its sequelae. The DSMB subsequently approved a revised protocol with laromustine dose reduction and recombinant growth factor support. The study was registered as NCT00112554 at http://www.clinicaltrials.gov.Keywords
This publication has 28 references indexed in Scilit:
- Development of an O6-alkylguanine–DNA alkyltransferase assay based on covalent transfer of the benzyl moiety from [benzene-3H]O6-benzylguanine to the proteinAnalytical Biochemistry, 2008
- Inhibition of human DNA polymerase β activity by the anticancer prodrug CloretazineBiochemical and Biophysical Research Communications, 2008
- Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating speciesLeukemia Research, 2008
- Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic miceNeuro-Oncology, 2007
- Bendamustine and cloretazine: alkylators with sharply contrasting activity in AML.Leukemia & Lymphoma, 2007
- Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazineMolecular Cancer Therapeutics, 2006
- Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazineMolecular Cancer Therapeutics, 2005
- 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M): II. Role of O 6 -alkylguanine-DNA alkyltransferase in cytotoxicityCancer Chemotherapy and Pharmacology, 2003
- Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in ratsAAPS PharmSci, 2002
- The Treatment of Acute Myeloid Leukemia in First Relapse: A Comprehensive Review of the LiteratureLeukemia & Lymphoma, 2002